Neuraxpharm Aims For Sales Of €400m By Year End
The Projected Total Represents Organic Growth Of 10%
After recently rebranding the company, Neuraxpharm has put expansion plans in place that have allowed it to reach over 70% of the European central nervous system market, resulting in projections of organic sales growth of 10% and gross sales of €400m for this year.
